673 |
B-RAF PROTO-ONCOGENE, SERINE/THREONINE KINASE |
BRAF |
B-RAF1 |
B-raf |
BRAF1 |
NS7 |
RAFB1 |
164757 |
1097 |
ENSG00000157764 |
OTTHUMG00000157457 |
P15056 |
PA25408 |
v-raf murine sarcoma viral oncogene homolog B1 |
B-RAF PROTO-ONCOGENE SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.37) (P94) (V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1). [SOURCE:UNIPROT/SWISSPROT;ACC:P15056] |
p94 |
Proto-oncogene B-Raf |
Serine/threonine-protein kinase B-raf |
5 |
BRAF1_HUMAN |
BRAF_HUMAN |
RAF |
T99089 |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.1 |
Human Readable Name | DRUGGABLE GENOME |
Target Subclass | 2.7.11.1 |
Target Main Class | Enzymes |
CancerCommons Reported Gene Name | BRAF (V660) E/K |
CancerCommons Reported Gene Name | BRAF |
CancerCommons Reported Gene Name | Pan-RAF |
CancerCommons Reported Gene Name | BRAF V600E |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
Interpro Acc | IPR001245 |
Uniprot Status | Swiss-Prot |
Interpro Type | Domain |
Human Readable Name | KINASE |
Gene Biotype | PROTEIN_CODING |
KINASE |
SERINE THREONINE KINASE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
CLINICALLY ACTIONABLE |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Response Type | predicted – resistant |
Indication/Tumor Type | ovarian cancer |
combination therapy | AMG 232 + Trametinib + Dabrafenib |
inhibitor (inhibitory) |
Clinical Status | late trials |
Clinical Status | early trials |
Clinical Status | case report |
n/a |
combination therapy | Panitumumab + Dabrafenib + Trametinib |
combination therapy | Vemurafenib + Panitumumab |
Clinical Status | late trials |
n/a |
combination therapy | Trametinib + Dabrafenib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
n/a |
combination therapy | Cetuximab + PLX4720 |
combination therapy | Vemurafenib + Cetuximab |
combination therapy | Cetuximab + Dabrafenib + SCH772984 |
inhibitor (inhibitory) |
combination therapy | Cetuximab + Encorafenib |
Indication/Tumor Type | colorectal cancer |
Response Type | resistant |
inhibitor (inhibitory) |
Indication/Tumor Type | melanoma |
Response Type | resistant |
Approval Status | Preclinical - Cell line xenograft |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Indication/Tumor Type | Advanced Solid Tumor |
Response Type | predicted – sensitive |
Response Type | resistant |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
Indication/Tumor Type | melanoma |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Reported Cancer Type | Melanoma |
n/a |
Approval Status | FDA approved |
Approval Status | Phase Ib/II |
combination therapy | Atezolizumab + Vemurafenib + Cobimetinib |
inhibitor (inhibitory) |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Indication/Tumor Type | Advanced Solid Tumor |
n/a |
combination therapy | Encorafenib + Binimetinib |
combination therapy | Encorafenib + Binimetinib + Cetuximab |
Evidence Type | Actionable |
n/a |
Indication/Tumor Type | melanoma |
Response Type | decreased response |
Approval Status | Preclinical |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
n/a |
combination therapy | Vemurafenib + Voruciclib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
inhibitor (inhibitory) |
Trial Name | Nexavar |
Novel drug target | Established target |
Clinical Status | preclinical |
inhibitor (inhibitory) |
Mechanism of Interaction | RAF serine/threonine protein kinase inhibitor |
Direct Interaction | yes |
n/a |
combination therapy | Pimasertib + Sorafenib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
inhibitor (inhibitory) |
Clinical Status | preclinical |
Variant Effect | reduced kinase activity |
Pathway | activation |
inhibitor (inhibitory) |
Direct Interaction | yes |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Indication/Tumor Type | colorectal cancer |
inhibitor (inhibitory) |
combination therapy | Bevacizumab + Temsirolimus + Doxil |
Indication/Tumor Type | ovarian carcinoma |
Response Type | sensitive |
n/a |
combination therapy | Atezolizumab + Vemurafenib + Cobimetinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
inhibitor (inhibitory) |
Mechanism of Interaction | Serine/threonine-protein kinase B-raf inhibitor |
Direct Interaction | yes |
BRAF | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
BRAF | Gene Symbol |
Target Class | Enzymes |
Target Subclass | EC:2.7.11.1 |
ENSG00000157764 | Ensembl Gene Id |
BRAF | Display Id |
B-RAF PROTO-ONCOGENE SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.37) (P94) (V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B1). [SOURCE:UNIPROT/SWISSPROT;ACC:P15056] | Description |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
BRAF1_HUMAN | Uniprot Id |
ENSG00000157764 | Ensembl Gene Id |
P15056 | Uniprot Accession |
Target Subclass | 2.7.11.1 |
Target Main Class | Enzymes |
673 | Entrez Gene ID |
CancerCommons Reported Gene Name | BRAF (V660) E/K |
CancerCommons Reported Gene Name | BRAF |
CancerCommons Reported Gene Name | Pan-RAF |
SERINE/THREONINE-PROTEIN KINASE B-RAF | Uniprot Protein Name |
BRAF_HUMAN | Uniprot Id |
673 | Entrez Gene Id |
Interpro Short Name | Ser-Thr/Tyr_kinase_cat_dom |
Interpro Name | Serine-threonine/tyrosine-protein kinase catalytic domain |
Uniprot Evidence | 1: Evidence at protein level |
KINASE, DRUGGABLE GENOME |
673 | CKB Entrez Id |
BRAF | CKB Gene Synonym |
B-raf | CKB Gene Synonym |
PA25408 | PharmGKB ID |
673 | Entrez Gene ID |
5 | CIViC Gene ID |
DRUG RESISTANCE, CLINICALLY ACTIONABLE |
ENSG00000157764 | Gene Symbol |
BRAF | Ensembl Id |
DRUGGABLE GENOME |
BRAF | Gene Symbol |
673 | Entrez Gene Id |
BRAF | MyCancerGenome Gene Symbol |
BRAF | MyCancerGenome Reported Gene Name |
RAFB1 | GENE_SYMBOL |
BRAF | GENE_SYMBOL |
Serine/threonine-protein kinase B-raf | UNIPROT |
673 | OncoKB Entrez Id |
NS7 | OncoKB Gene Synonym |
B-raf | OncoKB Gene Synonym |
BRAF1 | GO Gene Synonym |
RAFB1 | GO Gene Synonym |
SERINE THREONINE KINASE |
BRAF | Gene Symbol |
CLINICALLY ACTIONABLE |
673 | Gene ID |
B-RAF1 | dGene Synonym |
BRAF1 | dGene Synonym |
KINASE, SERINE THREONINE KINASE |
BRAF | TTD Gene Abbreviation |
T99089 | TTD Target ID |
Serine/threonine-protein kinase B-raf | Gene Name |
P15056 | UniProt ID |
KINASE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
CLINICALLY ACTIONABLE |
DRUG RESISTANCE |